Trevi Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Rosalind Advisors, Inc.(1.98%),Steven Salamon(1.98%)等
Trevi Therapeutics | 4:持股变动声明-董事 Mathers Edward T
Trevi Therapeutics | 4:持股变动声明-董事 Meeker David P
Trevi Therapeutics | 4:持股变动声明-董事 Heffernan Michael Thomas
Trevi Therapeutics | 4:持股变动声明-董事 Cassella James V
Trevi Therapeutics | 4:持股变动声明-董事 Colangelo Dominick
Trevi Therapeutics | 4:持股变动声明-高管 SCIASCIA THOMAS
Trevi Therapeutics | 4:持股变动声明-高管 Delfini Lisa
Trevi Therapeutics | 4:持股变动声明-高管 GOOD JENNIFER L
Trevi Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-New Enterprise Associates 16, L.P.(20.3%),NEA Partners 16, L.P.(20.3%)等
Trevi Therapeutics | 4:持股变动声明-高管 GOOD JENNIFER L
Trevi Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Rosalind Advisors, Inc.(1.34%),Steven Salamon(1.34%)等
Trevi Therapeutics | 4:持股变动声明-高管 Simon Farrell
Trevi Therapeutics | 4:持股变动声明-高管 Galletta Christopher
Trevi Therapeutics | 4:持股变动声明-高管 Clark David J
Trevi Therapeutics | 4:持股变动声明-高管 GOOD JENNIFER L
Trevi Therapeutics | 4:持股变动声明-高管 SCIASCIA THOMAS
Trevi Therapeutics | 4:持股变动声明-高管 Delfini Lisa
Trevi Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Venrock Healthcare Capital Partners II, L.P.(9.99%),VHCP Co-Investment Holdings II, LLC(9.99%)等
Trevi Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Fairmount Funds Management LLC(0.0%),Peter Harwin(0.0%)等
暂无数据